ArticleOncology letters2026
Transferrin receptor serves a role in promoting PANoptosis in thyroid cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PANoptosis is an emerging form of regulated cell death (RCD) that results from the interaction between necrosis, apoptosis and pyroptosis. The transferrin receptor (TFRC) is a suppressor in thyroid cancer (TC) and is involved in several RCD pathways, including ferroptosis, apoptosis, cuproptosis and necrosis. The present study aimed to assess how TFRC influences PANoptosis in TC and evaluate its underlying molecular mechanisms. Bioinformatics analyses were performed to identify coding genes associated with the expression of PANoptosis markers (Z-DNA-binding protein 1 and absent in melanoma 2) in The Cancer Genome Atlas-Thyroid Cancer (TCGA-THCA) dataset. Techniques such as PI/Calcein-AM and YO-PRO-1/PI staining, and western blotting were used to assess how TFRC influences PANoptosis in TC cells. Additionally, mRNA sequencing (mRNA-seq) was employed to identify differentially expressed (DE)-mRNA associated with TFRC. A total of 729 and 1,568 coding genes in the TCGA-THCA dataset demonstrated a significant association with ZBP-1 and AIM2 expression, respectively, involving regulation of immunity, apoptosis and necroptosis. Among these, TFRC was identified as a prognostic biomarker for TC and was downregulated in TC tissues and cells. Overexpression of TFRC increased TC cells undergoing pyroptosis, apoptosis and necroptosis, whilst it decreased the number of viable cells. Additionally, TFRC overexpression was associated with an elevation in the expression of cleaved-caspase (CASP)1, CASP1, cleaved-CASP3, CASP3, phospho-mixed lineage kinase domain-like and total-receptor-interacting serine/threonine-protein kinase 3, whereas TFRC knockdown was associated with the opposite effects. mRNA-seq identified 828 DE-mRNAs associated with TFRC. Enrichment analysis revealed that these DE-miRNAs regulate cell cycle, apoptosis, necrotic apoptosis, pyroptosis, oxidative stress and immunity. Furthermore, in the protein-protein interaction network constructed from DE-mRNAs, genes such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.